|
2022-07-13 |
2022-07-11 |
B
Purchase
|
Former 10% Owner
Large shareholder
|
24,190
+33.9%
414.37
US$1,293,753
|
24,190
+33.9%
|
414.37
|
US$1,293,753
|
|
|
2022-07-13 |
2022-07-08 |
B
Purchase
|
Former 10% Owner
Large shareholder
|
54,165
-14.5%
290.11
US$3,346,825
|
54,165
-14.5%
|
290.11
|
US$3,346,825
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
General Counsel
Officer
|
83,975
+16.0%
376.15
US$2,539,373
|
83,975
+16.0%
|
376.15
|
US$2,539,373
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
See Remarks
Officer
|
3,759
-7.5%
3.19
US$11,991
|
3,759
-7.5%
|
3.19
|
US$11,991
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
See Remarks
Executive Director
|
11,974
-7.5%
3.19
US$38,197
|
11,974
-7.5%
|
3.19
|
US$38,197
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
Chief Development Officer
Officer
|
4,001
-8.0%
3.19
US$12,763
|
4,001
-8.0%
|
3.19
|
US$12,763
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
Chief Scientific Officer
Officer
|
3,759
-5.2%
3.19
US$11,991
|
3,759
-5.2%
|
3.19
|
US$11,991
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
See Remarks
Officer
|
3,759
-7.5%
3.19
US$11,991
|
3,759
-7.5%
|
3.19
|
US$11,991
|
|
|
2021-10-20 |
2021-10-19 |
S
Sale
|
Chief Medical Officer
Officer
|
3,759
-7.5%
3.19
US$11,991
|
3,759
-7.5%
|
3.19
|
US$11,991
|
|
|
2020-09-01 |
2020-09-01 |
B
Purchase
|
Large shareholder
|
4,672,897
+33.4%
2.68
US$12,499,999
|
4,672,897
+33.4%
|
2.68
|
US$12,499,999
|
|
|
2020-06-12 |
2020-06-11 |
B
Purchase
|
Large shareholder
|
12,677,490
+958.6%
2.50
US$31,693,725
|
12,677,490
+958.6%
|
2.50
|
US$31,693,725
|
|
|
2020-01-13 |
2020-01-09 |
S
Sale
|
Large shareholder
|
50,000
-3.7%
5.00
US$250,010
|
50,000
-3.7%
|
5.00
|
US$250,010
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
Topper James N
Non-Executive Director
Large shareholder
|
375,887
+38.6%
15.00
US$5,638,305
|
375,887
+38.6%
|
15.00
|
US$5,638,305
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
Pivotal bioVenture Partners Fund I, L.P.
Large shareholder
|
337,724
+40.1%
15.00
US$5,065,860
|
337,724
+40.1%
|
15.00
|
US$5,065,860
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
Clarus Lifesciences III, L.P.
Large shareholder
|
453,395
+38.8%
15.00
US$6,800,925
|
453,395
+38.8%
|
15.00
|
US$6,800,925
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
Preston Heather
Non-Executive Director
Large shareholder
|
337,724
+40.1%
15.00
US$5,065,860
|
337,724
+40.1%
|
15.00
|
US$5,065,860
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
Sofinnova Venture Partners IX, L.P.
Large shareholder
|
337,724
+40.1%
15.00
US$5,065,860
|
337,724
+40.1%
|
15.00
|
US$5,065,860
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
TPG Group Holdings (SBS) Advisors, Inc.
|
262,539
+34.6%
15.00
US$3,938,085
|
262,539
+34.6%
|
15.00
|
US$3,938,085
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
ASTRAZENECA PLC
Large shareholder
|
246,666
+12.9%
15.00
US$3,699,990
|
246,666
+12.9%
|
15.00
|
US$3,699,990
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
Frazier Life Sciences VIII, L.P.
Large shareholder
|
375,887
+38.6%
15.00
US$5,638,305
|
375,887
+38.6%
|
15.00
|
US$5,638,305
|
|
|
2018-10-02 |
2018-09-28 |
B
Purchase
|
GALAKATOS NICHOLAS
Non-Executive Director
Large shareholder
|
453,395
+38.8%
15.00
US$6,800,925
|
453,395
+38.8%
|
15.00
|
US$6,800,925
|
|
|
2018-10-01 |
2018-09-28 |
B
Purchase
|
Novo Holdings A/S
Large shareholder
|
1,089,835
+99.8%
15.00
US$16,347,525
|
1,089,835
+99.8%
|
15.00
|
US$16,347,525
|
|